Tag: inhibitors
Effect of P2Y12 Inhibitors on Organ Support-Free Survival in COVID-19 Patients
n this randomized clinical trial of critically ill participants hospitalized for COVID-19, treatment with a P2Y12 inhibitor did not improve the number of days alive and free of cardiovascular or respiratory organ support.... read more
Oral PCSK9 Inhibitor Could Help Reduce LDL-C by 60%
New research from a phase 2b trial presented at American College of Cardiology meeting (ACC) 2023 suggests an oral PCSK9 inhibitor could help reduce LDL-C by 60% in patients with or at-risk for atherosclerotic cardiovascular... read more
Targeted Immunomodulation: A Primer for Intensivists
Targeted immunomodulation is a topic that gained wide interest from translational researchers in the past decades, yet immunomodulatory drugs were not frequently administered to intensive care patients. The coronavirus... read more
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19
Among critically ill patients with COVID-19, treatment with an antiplatelet agent, compared with no antiplatelet agent, had a low likelihood of providing improvement in the number of organ support–free days within 21 days. The... read more
Thromboinflammation and Antithrombotics in COVID-19
Thrombotic complications of SARS-CoV-2 infection were recognized early in the pandemic, when infected patients often presented with abnormal coagulation findings and acute macrovascular obstruction, and evidence of pulmonary... read more
Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema
This study compared the effect of placebo versus the bradykinin B2 receptor antagonist icatibant on symptoms of ACE inhibitor–associated angioedema in a mixed race population of patients. The study does not support the... read more
Antiviral Drug Discovery and Development
This book summarizes state-of-the-art antiviral drug design and discovery approaches starting from natural products to de novo design, and provides a timely update on recently approved antiviral drugs and compounds in advanced... read more
Plasma Hyaluronan, Hyaluronidase Activity and Endogenous Hyaluronidase Inhibition in Sepsis
Elevated plasma hyaluronan levels coincided with a concomitant decrease in effective plasma HYAL activity and increase of endogenous plasma HYAL inhibition both in experimental and clinical sepsis. In acute pancreatitis,... read more
WHO Recommends Two New Drugs for COVID-19 Treatment
WHO has recommended two new drugs for COVID-19, providing yet more options for treating the disease. The extent to which these medicines will save lives depends on how widely available and affordable they will be. The... read more
Organophosphorus Compounds and Oximes
Organophosphorus (OP) pesticides and nerve agents still pose a threat to the population. Treatment of OP poisoning is an ongoing challenge and burden for medical services. Standard drug treatment consists of atropine and... read more
Intubation Timing As Determinant Of Outcome in Patients with ARDS By COVID-19 Infection
In COVID-19 patients, late intubation, Pafi ... read more
Selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors in pregnancy
This position statement provides guidance for the monitoring, care, and follow-up of newborns exposed to selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) in utero. Depression... read more
Drug Treatments for COVID-19
Corticosteroids and interleukin-6 inhibitors probably confer important benefits in patients with severe covid-19. Janus kinase inhibitors appear to have promising benefits, but certainty is low. Azithromycin, hydroxychloroquine,... read more
On Cytokines, Fluvoxamine and COVID-19
Early in the COVID-19 pandemic, the role of ‘cytokine storm’ in patients with severe course was raised. Indeed, this triggered multiple investigations centred around calming excessive inflammation with pharmacotherapies... read more
